Luye Pharma Announces 2025 Financial Results
- New product sales up 56.8% -
- Net profit attributable to parent company up 31.1% -
Shanghai, March 31, 2026 -- Luye Pharma Group (2186.HK) today announced its annual results for fiscal year 2025 and the latest developments.
In the reporting period, the group’s revenue was ...
April 01,2026
Luye Pharma Forms Strategic Partnership with Sinopharm Group and Sinopharm CNCM to Commercialize Mimeixin® and Other Products
Shanghai, March 13, 2026 — Luye Pharma Group today announced a strategic partnership with Sinopharm Group Co. Ltd. (Sinopharm Group) and its subsidiary China National Medicines Corporation Ltd. (Sinopharm CNCM).
In this partnership, the three parties will collaborate with each ...
March 13,2026
08
2026-01
NMPA Accepts the NDA for Luye Pharma’s Ruoxinlin® for the New Indication of Generalized Anxiety Disorder
24
2025-12
Luye Pharma Grants Nhwa Exclusive Rights to Commercialize Three Long-Acting Injectable Antipsychotics in the Chinese Mainland
07
2025-12
Luye Pharma’s Five New Products Included in China’s 2025 National Reimbursement Drug List or Commercial Insurance Innovative Drug List
24
2025-11
Luye Pharma Receives FDA Clearance of IND Application for Its Next-generation 5-HT2AR Inverse Agonist/5-HT2CR Antagonist LY03017
28
2025-08
Luye Pharma Announces 2025 Half-Year Results
18
2025-08
All Patients Enrolled for the Phase III Clinical Trial of Luye Pharma’s Ruoxinlin® for Treating Generalized Anxiety Disorder
03
2025-08
First Subject Enrolled in Phase 1 Clinical Trial for Luye Pharma’s Investigational Antidepressant Targeting NET/DAT/GABAAR
10
2025-04
Luye Pharma Launches Its Transdermal Patch Rotigotine Luye in the UK for the Treatment of Parkinson’s Disease and Restless Legs Syndrome
07
2025-04
Luye Pharma’s Class 1 Innovative Antidepressant Ruoxinlin® Approved for Marketing in Macao
07
2025-04
Luye Pharma Announces U.S. Launch of ERZOFRI® (paliperidone palmitate) Extended-Release Injectable Suspension for the Treatment of Schizophrenia and Schizoaffective Disorder
